糖尿病大鼠胰岛β细胞Fox01表达对细胞凋亡的影响

以高糖高脂饲料及链脲佐菌素诱导SD大鼠建立2型糖尿病模型,结果发现叉头转录因子(Fox01)[细胞核内(15.00+1.15 vs 6.45±0.62)%,P<0.05]、半胱天冬蛋白酶3(caspase-3)[(23.73±1.48vs 6.30±2.20)%,P<0.01]在糖尿病大鼠胰岛β细胞的表达和β细胞凋亡率[(22.29±1.84 vs 6.25±2.42)%,P<0.01]均高于正常大鼠;并且Fox01(核内)与caspase-3高表达的胰岛细胞正是发生凋亡的胰岛细胞.因此,Fox01可能参与2型糖尿病胰岛β细胞凋亡的调控.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.     

The new treatment target of diabetes: islet β-cell mass

Pancreatic islet β-cell mass is regulated by β-cell replication, nengenesis, apnptosis and cell size. β-cetl mass in diahetic patients is conspicuously less than that in normal subjects. Induction of β-cell regeneration and inhibition of β-cell apoptosis is the new target of diabetes treatment.